ALSO NOTED: Valeant to halve its workforce; Pharma testing mobile marketing waters;

> Valeant Pharmaceuticals said it will cut 130 jobs in the U.S. in Mexico, on top of the 1,250 positions set to go when the company sells off its European subsidiaries. Valeant report

> As text-messaging grows in the U.S., more pharma companies are dipping their toes into mobile marketing via the brief communications, according to a report from PharmaVoice. Report

> Australian drug companies are joining the chorus of firms asking their governments to cut corporate taxes or suffer a pharma exodus. Report

> Glenmark Pharmaceuticals expects to launch five drugs each quarter of 2008, plus file 25 apps for new generic drugs, chairman Glenn Saldanha said. Report

> Discovery Laboratories got an "approvable" letter from the FDA on its Surfaxin med for prevention of respiratory distress in  premature babies. Release

> China Pharma Holdings reported a 62 percent spike in revenue to $11.7 million; profits grew even more, by 76.5 percent to $4.2 million. Release

> A major shareholder in Enzon Pharmaceuticals is calling for the resignation of several board members for approving the "runaway" compensation of CEO Jeffrey Buchalter. Report

> Penwest Pharmaceutical lost 41 cents per share, or $10.3 million, in the first quarter as revenue dropped to $739,000. Report

> The transatlantic EUSA Pharma has spun off its monoclonal antibody research operation along with a development program for leukemia as it narrows its focus to late-stage drug development and marketing. EUSA report

> Sepracor has struck a licensing deal with Arrow International Limited for the intellectual property rights related to stable sterile steroid suspension formulations and other applicable nebule technology for the use in developing ciclesonide, a corticosteroid. Sepracor report

> Nucryst Pharmaceuticals has shaken up its management and shelved one of its development programs. Nucryst report

Special Report... CEO Pay: Who makes what in Big Biotech? Report

And Finally... Some 23 percent of Americans admitted lending their prescription meds to someone else, and 27 percent confessed to borrowing them. Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.